Alzheimer’s disease (AD) progression involves microglial activation, and restoring or maintaining microglia homeostasis is a therapeutic approach to fight against AD.
Aribio Co. Ltd. signed a $600 million license deal with Acino International AG, an Arcera Life Sciences subsidiary, granting the latter commercial rights to its oral Alzheimer’s disease therapy, AR-1001, in select countries including the Middle East.
Mindimmune Therapeutics Inc. has been awarded a grant by Rhode Island Life Science Hub to accelerate preclinical development work on MITI-101 for the treatment of mild to moderate Alzheimer’s disease. The award will accelerate development work needed to start first-in-human studies.
Astrocytes are crucial for brain homeostasis and synaptic activity under healthy conditions, and are activated during neuroinflammation, neural damage and neurodegeneration, such as in Alzheimer's disease (AD).
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuronal loss and the accumulation of amyloid plaques and neurofibrillary tangles, ultimately leading to cognitive decline. Despite significant research efforts, no existing treatment has proven effective enough to stop or reverse the progression of the disease.
History has repeated itself for Prothena Corp. plc, which has reported a second phase III miss for birtamimab in the treatment of light chain amyloidosis. Announcing the trial failure, the Dublin-based company said it is planning “a substantial reduction” of its organization.
Researchers at North China Electric Power University and collaborators have developed novel radiolabels for the membrane-bound monoamine oxidase-B that feature a coumarin core.
Aquinnah Pharmaceuticals Inc. has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer's disease and frontotemporal dementia.
The third most significant genetic risk factor for late-onset Alzheimer’s disease is a mutation in the clusterin (CLU) gene that disrupts the expression of sCLU, a cytoprotective protein involved in preventing protein aggregation and promoting the clearance of misfolded proteins.
Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a non-tradeable contingent value right entitling the holder to potentially collect $2 per share more in cash, payable following the first commercial sale of the phase II-ready VG-3927, a small-molecule triggering receptor expressed on myeloid cells 2 (TREM2) antagonist for Alzheimer’s disease, if achieved within a specific period. Watertown, Mass.-based Vigil’s stock closed May 22 at $7.88, up $5.57, or 241%.